|Bid||69.19 x 1200|
|Ask||69.79 x 800|
|Day's Range||69.13 - 70.30|
|52 Week Range||65.06 - 100.23|
|Beta (3Y Monthly)||0.77|
|PE Ratio (TTM)||19.70|
|Earnings Date||Jul 26, 2019|
|Forward Dividend & Yield||4.28 (6.09%)|
|1y Target Est||84.92|
J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2019 and raises 2019 guidance for operational sales growth for the second time this year.
Bernstein analyst Ronny Gal says the spread between the current stock price and AbbVie’s offer is fair and it is time to take the foot off the gas.
AbbVie (NYSE: ABBV ) said Monday it acquired Seattle-based biopharmaceutical company Mavupharma for an undisclosed amount. Mavupharma is focused on approaches to target the STING (STimulator of INterferon ...
NORTH CHICAGO, Ill., July 15, 2019 /PRNewswire/ -- AbbVie (ABBV) announced today that it has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer. STING pathway signaling plays an important role in the generation of an immune response directed at tumors, and enhancing STING signaling has shown promise in a variety of tumor models. STING pathway stimulation has the potential to increase the susceptibility of tumors and broaden treatment options for patients.
The FDA accepts Neurocrine's (NBIX) NDA for opicapone, developed as an adjunctive treatment to levodopa/carbidopa for patients with Parkinson's disease, who currently experience OFF episodes.
NORTH CHICAGO, Ill. , July 11, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its second-quarter 2019 financial results on Friday, July 26 before ...
J&J's (JNJ) cancer drugs should continue to perform well in second-quarter 2019. Generic/biosimilar headwinds will hurt Pharma unit's sales.
Here are two pharmaceutical companies that are presently being downgraded by analysts but that are expected to gain strength as the year progresses. It’s an inversion of the axiom, “Past performance is not guarantee of future results.” The risk of investing in them may be large but so are the potential rewards for farsighted investors. AbbVieAbbVie (ABBV) has been experiencing a drop in its shares for the last several months. The major reason for its decline is its biologic immunology drug Humira accounting for the biggest part of its revenue.Humira sales have been weaker lately. Rated as one of the top-selling drugs in 2018, Humira started losing a competition with cheaper medicines in 2019. In the first quarter of this year, it brought in revenue of $4.45 billion, which is 5.6% less than the company’s last year revenue.AbbVie faced other setbacks. Its cancer drug Rova-T failed to become a great commercial success. AbbVie’s testing of Venclexta, a multiple myeloma drug, was not successful either and negatively affected its stock. Over the past 12 months, AbbVie’s shares dipped 14%. Its net earnings decreased to $1.65 per share in the first quarter of 2019, from $1.74 per share a year earlier.On June 25, AbbVie announced a definitive agreement to acquire Allergan (AGN) in a cash and stock transaction for a total consideration of $63 billion. The news worked to its financial disadvantage. As soon as AbbVie’s intentions became known, its stock sank 16%, because investors estimated its plans as a mistake. When investors recovered from the news, AbbVie’s stock went up - but only slightly so. As a result, for the last six months, analysts have strongly been advising to put any investment in AbbVie on hold. As of writing, the average price given by analysts to the company’s shares is $79.33, with only 10.95% upside. Yet there are positive signs that AbbVie can soon stop its downward progression. It has recently signed lucrative deals with Mylan NV and Amgen Inc (AMGN). It is also working on a new cancer drug called Imbruvica. The drug may help move abnormal B cells out of their nourishing environment in the lymph nodes, bone marrow, and other organs.In June, Imbruvica was ranked as the fifth drug thought to become a blockbuster in the near future. According to EvaluatePharma, AbbVie’s new drug may bring it $9.5 billion in sales in 2024. The company’s two other drugs – Orilissa and Skyrizi – are also expected to sell well and thus enlarge its profits. After the projection made by EvaluatePharma, Goldman Sachs analyst Terence Flynn increased his price target to $84. He thinks that the sales from AbbVie’s cancer drugs and new immunology drugs will generate enough revenue to balance out the losses brought by Humira. Other analysts hope for the company’s strength, too. As AbbVie approaches its Q2 earnings release, analysts expect that it will report $2.21 per share, which would represent year-over-year growth of 10.5%. The blogger Wolf Report agrees: “ I'm bullish on AbbVie. It remains one of my largest pharma stocks, and I'm willing to add more, should the opportunity present itself. And I believe that it now has, and may even improve going forward.”Analyst Ratings & Price Targets on AbbVie BiogenBiogen (BIIB) had a rough start of the year. Within the first six months of 2019, the company tumbled by 22.3%, erasing 17 billion in valuation. There are several reasons for Biogen’s unsightly decline. One is the failure of the Alzheimer’s project aducanumab. At two late-stage trials it became clear that the anti-amyloid MAb, which Biogen believed would clear amyloid lesions, could not prevent the disease.Biogen’s shares also dropped because of the competition with Novartis (NVS). Its drug Spinraza that cures pediatric spinal muscular atrophy and generates the bulk of its profits can be upstaged by Novartis’s recently approved medicine Zolgensma. The Institute for Clinical and Economic Review (ICER) said in January that Zolgensma, which also treats spinal muscular atrophy in small children, could be more cost-effective than Biogen’s drug with a one-time price of $2 million. Biogen’s multiple-sclerosis franchise also failed to live up to its promise, undermined by a competition with such companies as Roches and Novartis. A preferable alternative to Biogen’s main MS medicines, Tysarabi and Tecfidera, Roches’ drug Ocrevus has been diminishing Biogen’s profits since the third quarter of 2017. This year, the competition between the MS medicine producers intensified, when Novartis introduced Mayzent that costs about $88,500 a year. This is about 7% less than Biogen’s Tysarabi and Tecfidera.But Biogen still has several ongoing medical trials to its credit. It is presently developing its next MS medicine Vumerity, whose approval might happen later this year. Investors may also follow Biogen’s earlier-stage pipeline for inherited disease of the eye, pain management, and cardiovascular disease. Biogen might also make several acquisitions in 2019. There are rumors that its recent purchase of Nightstar Therapeutics, a gene therapy company, will be followed by other acquisitions. Analysts suggest that such companies as Neurocrine Bioscience (NBIX), Sage Therapeutics (SAGE), and Ionis Pharmaceuticals (IONS) would enhance Biogen’s holdings. But even if no additional purchase is made, Nightstar Therapeutics can become for Biogen a useful springboard for building an eye disease franchise that will push its profit up in the coming several years. True, some analysts advise not to invest in Biogen for the time being, but there are others who are bullish on its stock. H.C. Wainwright analyst Andrew Fein maintains a Buy rating on Biogen, with a price target of $300. Analyst Ratings & Price Targets on Biogen Inc
AbbVie Inc (NYSE: ABBV ) has selected a second target under an existing collaboration with CytomX Therapeutics Inc (NASDAQ: CTMX ) for probody technology. This development is “incrementally positive” for ...
Biotech exploded with "megadeals" in the first half of 2019 as pharmaceutical companies Bristol-Myers Squibb and AbbVie announced acquisitions worth a combined $137 billion.
With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION ...
There's nothing more satisfying that getting money for doing nothing. That's why dividend stocks hold so much appeal for portfolios. After a one-time investment, top dividend stocks will pay you year in and year out, for doing nothing except holding them. This has to be one of the greatest forces in all of investing. And everyone likes getting money for free.To that end, high-yielding dividend stocks could be an income seeker's or retiree's best friend.By focusing on those stocks with above-average yields, investors can truly supercharge their current income. The best part is that many of the highest-yielding dividend stocks in the S&P 500 aren't exactly risky names. We're talking huge companies with plenty of cash flows and earnings to back-up those payouts.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Best Stocks for 2019: A Volatile First Half The truth is, there are plenty of big-time stocks that are producing some serious income for their shareholders. Here are five of the best high-yielding dividend stocks in the S&P 500. Macerich Company (MAC)Dividend Yield: 9%Source: Shutterstock With a nearly 9% yield, Macerich (NYSE:MAC) tops the list as one of the highest-yielding dividend stocks in the S&P 500. That high yield can be explained in two ways: For starters, MAC is a real estate investment trust (REIT). As a REIT, the firm is required to pay out the bulk of its cash flows to investors as dividends in order to take advantage of lucrative tax breaks.The second reason is that Macerich is a retail real estate owner -- specifically a mall owner. As e-commerce has taken hold, stocks like MAC have taken it on the chin.Today, MAC stock sits at new eight-year lows.This could be a prime time to load up on such a high-yielding dividend stock. The reason is that MAC doesn't own slouch malls. Yes, junky Class B malls are dying, but premium Class A shopping malls are thriving. MAC owns 48 of these high-end malls and they continue to see high occupancy rates -- over 95% -- and sales per square foot -- around $869.Meanwhile, the firm continues to change its tenant mix to involve more experiences, dining and entertainment options. This has only boosted traffic and sales further.The point is, MAC is being unfairly cast aside with the lower mall operators. This has shown up in its ability to boost critical funds from operations (FFO) measures over the retail Armageddon. It has also continued to raise its standard dividend as well as pay special ones.All in all, Macerich is one high-yielding dividend stock to snag-up. Iron Mountain Inc (IRM)Dividend Yield: 7.64%Source: Orin Zebest via FlickrLike Macerich, Iron Mountain (NYSE:IRM) is also a REIT, but IRM is a tad bit different. The firm makes its money by owning records and data storage facilities around the world. In fact, Iron Mountain is the biggest provider of such facilities with more than 1,400 different locations.It turns out this is an incredibly profitable and needed niche. Key customers include nearly everyone in the Fortune 1000 as well as various government organizations. With retention rates as high as 98%, IRM is able to pull in some hefty cash flows from the "rent" it charges these customers. Last year, it was able to grow its total FFO by nearly 19% and boost its dividend by over 6%.The best part is that Iron Mountain continues to evolve. It's no secret that digital records and data creation is growing by leaps and bounds. To this end, IRM has expanded in datacenter, cloud and digital hard drive access for its clients.Given its leadership position in physical document storage, the firm has had great success in upselling these digital products to customers. And with higher margins for cloud storage, IRM should be able to keep the growth coming for years. * 7 A-Rated Stocks to Buy for the Rest of 2019 And yet, because of its quirky nature, investors don't really pay too much attention to Iron Mountain. That fact provides it with a whopping 7.64% dividend yield. Philip Morris International (PM)Dividend Yield: 5.66%Source: Taber Andrew Bain Via FlickrWe all know smoking is dying a quick death here in the United States. Even e-cigarettes are getting the evil eye from regulators, which is just fine for tobacco stock Philip Morris International (NYSE:PM).The key for PM is the "international" in its name. The firm operates and sells tobacco in over 180 countries and territories with the U.S. not being one of them. Emerging markets such as Indonesia, Russia, China, and India make up the bulk of the firms' revenues.And those revenues continue to rise as smoking still carries some "cool" factor in these regions and is considered a small luxury. All in all, PM sold more than $29.6 billion dollars' worth of tobacco last year -- a 3.1% year-over-year jump.Philip Morris' future looks rosy as well.Big tobacco enjoys some big pricing power. Nicotine is an addictive substance and PM is able to pass on price increases to cover costs to consumers pretty easily. Secondly, the firm's IQOS heated-tobacco delivery system is seeing some very impressive numbers. Shipments for IQOS jumped 20% to reach 11.5 billion units in the firm's most recent quarter. All of this continues to strengthen the firm's cash flows, bottom line, and dividend prowess.The reality is, PM is one of the highest yielding dividend stocks because it's a hated vice firm. Not because fundamentals are bad. AbbVie (ABBV)Dividend Yield: 5.71%Source: Shutterstock The giant pharmaceutical firms have long been great dividend stocks. This includes biotech king AbbVie (NASDAQ:ABBV). Driving that fact has been its blockbuster drug Humira.Last year alone, the autoimmune-disease medication brought in nearly $20 billion for ABBV -- an increase of 8.2% over 2017's numbers. The drug has continued to drive ABBV's dividend -- currently at almost 6%.The problem is, Humira is facing the proverbial patent cliff sooner than later. Given that the drug is responsible for the bulk of AbbVie's revenues, this cliff shouldn't be taken lightly. And that's one of the reasons why the dividend stocks yield is so high.However, ABBV has a plan to replace that missing revenue. To begin with, the firm is buying out fellow biotech rival Allergan (NYSE:AGN). AGN features hits like Botox and other blockbusters in its umbrella. Meanwhile, AbbVie has recently scored several approvals that could turn into real cash cows over time. Add in its rich pipeline that is now more robust from the AGN buy and you have a recipe for continued cash flows. * 10 Stocks That Should Be Every Young Investor's First Choice For investors, there's plenty of potential in the dividend stock and you can grab that potential at a very high yield. Williams (WMB)Dividend Yield: 5.35%Source: Shutterstock Pipeline firms have often been called the "toll roads of the energy sector." That's because they are paid on the volume of oil and natural gas flowing through their systems. After a few years of simplification, the sector is now back to those roots. That includes top pipeline firm Williams (NYSE:WMB).WMB owns plenty of top-notch natural gas assets in key areas such as the Marcellus shale and the DJ Basin. These assets feature plenty of cash flows tied to their volumes. This provides less risk for Williams as many of these assets are paid via so-called "take or pay" contracts. And WMB's continues to add capacity and expansions to these prime pipelines and gathering systems. This will help expand WMB's cash flows further down the road.These moves seem to be working.Last quarter, WMB saw a big 12% boost to its quarter-over-quarter cash flow from operations, and a big 8% jump in its distributable cash flows. With that, management expects to be able to grow its dividend payout by between 10% and 15% this year. That's pretty impressive considering that WMB already yields 5.35%. With a full slate of expansion projects for the next few years, Williams should be able to keep the growth coming for years to come.For investors, pipelines have historically been some of the best dividend stocks. WMB is continuing that tradition.At the time of writing, Aaron Levitt did not hold a position in any stock mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Best Stocks for 2019: A Volatile First Half * 7 Simple Ways for Young Investors to Invest Their First $1,000 * 6 Stocks to Buy Based on Insider Buying The post The S&P 500as 5 Best Highest-Yielding Dividend Stocks appeared first on InvestorPlace.
AbbVie stock fell on its $63 billion plan to acquire Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?
ObsEva (OBSV) completes patient recruitment in the second pivotal phase III study evaluating linzagolix for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids.
The Zacks Analyst Blog Highlights: Amazon, UnitedHealth, AbbVie, Simon Property and Autodesk
AbbVie's (ABBV) stock suffers a poor run on the bourses due to pipeline setbacks, Humira sales erosion in EU and its proposed offer to buy Allergan.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.